{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:27:26Z","timestamp":1793741246201,"version":"4.6.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ekir.2026.107044","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:11:27Z","timestamp":1787328687000},"page":"107044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the B-Cell Activating Factor and a Proliferation-Inducing Ligand Pathway in IgAN: From Disease Pathogenesis to Clinical Trial Evidence"],"prefix":"10.1016","volume":"11","author":[{"given":"George","family":"Vasquez-Rios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Rajasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Coca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cravedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk N.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Sanchez","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.107044_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.107044_bib2","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1093\/ndt\/gfaf084","article-title":"CKD progression, kidney failure, and mortality among US patients with IgA nephropathy","volume":"40","author":"Sim","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.107044_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.107044_bib4","series-title":"FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease","year":"2021"},{"key":"10.1016\/j.ekir.2026.107044_bib5","series-title":"FDA approves a new treatment for primary immunoglobulin A nephropathy","year":"2025"},{"key":"10.1016\/j.ekir.2026.107044_bib6","author":"Therapeutics"},{"key":"10.1016\/j.ekir.2026.107044_bib10","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 2","key":"10.1016\/j.ekir.2026.107044_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/nep.14349","article-title":"The epidemiology of IgA nephropathy: East versus West","volume":"29","author":"Barbour","year":"2024","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2026.107044_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ekir.2026.107044_bib13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000500142","article-title":"A global evolutionary trend of the frequency of primary glomerulonephritis over the past four decades","volume":"5","author":"Woo","year":"2019","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.ekir.2026.107044_bib14","doi-asserted-by":"crossref","first-page":"c337","DOI":"10.1159\/000319594","article-title":"Global evolutionary trend of the prevalence of primary glomerulonephritis over the past three decades","volume":"116","author":"Woo","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ekir.2026.107044_bib15","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.3390\/jcm10194501","article-title":"Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment","volume":"10","author":"Knoppova","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ekir.2026.107044_bib16","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s00467-024-06361-1","article-title":"Are children with IgA nephropathy different from adult patients?","volume":"39","author":"Su","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2026.107044_bib17","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00467-012-2139-3","article-title":"Comparison of clinicopathological features between children and adults with IgA nephropathy","volume":"27","author":"Wang","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2026.107044_bib18","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s10157-023-02316-2","article-title":"Prognostic factors of IgA nephropathy presenting with mild proteinuria at the time of diagnosis (a multicenter cohort study)","volume":"27","author":"Shirai","year":"2023","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2026.107044_bib19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00281-021-00883-8","article-title":"IgA glycosylation and immune complex formation in IgAN","volume":"43","author":"Suzuki","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.ekir.2026.107044_bib20","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"JASN"},{"key":"10.1016\/j.ekir.2026.107044_bib21","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1523-1755.2005.67107.x","article-title":"IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells","volume":"67","author":"Novak","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.107044_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000382134","article-title":"New insights into the pathogenesis of IgA nephropathy","volume":"1","author":"Novak","year":"2015","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.ekir.2026.107044_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad025","article-title":"Immune abnormalities in IgA nephropathy","volume":"16","author":"Gentile","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.107044_bib24","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.34067\/KID.0002382022","article-title":"The gut and kidney cross talk in immunoglobulin-A nephropathy","volume":"3","author":"Sanchez-Russo","year":"2022","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2026.107044_bib25","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.ekir.2020.08.009","article-title":"Why target the gut to treat IgA nephropathy?","volume":"5","author":"Barratt","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.107044_bib26","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.kint.2025.01.014","article-title":"Treatment of patients with IgA nephropathy: a call for a new paradigm","volume":"107","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.107044_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1737992","article-title":"Aberrant signaling in tonsillar B cells producing pathogenic O-glycoforms of IgA1 in IgA nephropathy","volume":"17","author":"Yamada","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.107044_bib28","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.3390\/biomedicines10123027","article-title":"Mucosal immune system dysregulation in the pathogenesis of IgA nephropathy","volume":"10","author":"Kano","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ekir.2026.107044_bib29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0272-6386(03)00743-1","article-title":"IgA1 molecules produced by tonsillar lymphocytes are under-O-glycosylated in IgA nephropathy","volume":"42","author":"Horie","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.107044_bib30","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ekir.2024.11.007","article-title":"Patients with immunoglobulin A nephropathy show abnormal frequencies of B cell subsets, unconventional T cells, and high levels of galactose-deficient IgA1\u2013coated gut bacteria","volume":"10","author":"Gentile","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.107044_bib31","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ndt\/gfaa264","article-title":"High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients","volume":"36","author":"Sallustio","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.107044_bib32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/19490976.2017.1299311","article-title":"Regulation of humoral immunity by gut microbial products","volume":"8","author":"Kim","year":"2017","journal-title":"Gut Microbes"},{"key":"10.1016\/j.ekir.2026.107044_bib33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2007.04.014","article-title":"Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine April","volume":"26","author":"He","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.ekir.2026.107044_bib34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ekir.2026.107044_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/cei\/uxad024","article-title":"Features of BAFF and April receptors on circulating B cells in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"213","author":"Shimojima","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ekir.2026.107044_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.smim.2006.04.004","article-title":"BAFF, April and human B cell disorders","volume":"18","author":"Tangye","year":"2006","journal-title":"Semin Immunol"},{"key":"10.1016\/j.ekir.2026.107044_bib37","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in B cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.107044_bib38","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/ni829","article-title":"DCs induce CD40-independent immunoglobulin class switching through BLyS and April","volume":"3","author":"Litinskiy","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ekir.2026.107044_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.ekir.2026.107044_bib40","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora\u2013dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2026.107044_bib41","article-title":"Pathogenic role of a proliferation-inducing ligand (April) in murine IgA nephropathy","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2026.107044_bib42","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s10147-024-02611-2","article-title":"Current status of BAFF targeting immunotherapy in B-cell neoplasm","volume":"29","author":"Tagami","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ekir.2026.107044_bib43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ekir.2026.107044_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/nep.70139","article-title":"B cell activating factor does not play a pivotal role in the synthesis of aberrantly glycosylated IgA","volume":"30","author":"Kim","year":"2025","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2026.107044_bib45","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1073\/pnas.0307348101","article-title":"Impaired IgA class switching in APRIL-deficient mice","volume":"101","author":"Castigli","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2026.107044_bib46","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.coi.2005.04.005","article-title":"The role of April and BAFF in lymphocyte activation","volume":"17","author":"Schneider","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ekir.2026.107044_bib47","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased April expression induces IgA1 aberrant glycosylation in IgA nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ekir.2026.107044_bib48","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5301\/jn.5000218","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2026.107044_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13502","article-title":"A proliferation-inducing ligand increase precedes IgA nephropathy recurrence in kidney transplant recipients","volume":"33","author":"Mart\u00edn-Penagos","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ekir.2026.107044_bib50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clim.2007.11.003","article-title":"Increase in B-cell-activation factor (BAFF) and IFN-gamma productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy","volume":"126","author":"Goto","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ekir.2026.107044_bib51","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.humimm.2014.08.205","article-title":"Capsaicin induces high expression of BAFF and aberrantly glycosylated IgA1 of tonsillar mononuclear cells in IgA nephropathy patients","volume":"75","author":"Shao","year":"2014","journal-title":"Hum Immunol"},{"key":"10.1016\/j.ekir.2026.107044_bib52","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1681\/ASN.2015060677","article-title":"The role of TNF superfamily Member 13 in the progression of IgA nephropathy","volume":"27","author":"Han","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.107044_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262010055","article-title":"Transcriptomic signatures in IgA nephropathy: from renal tissue to precision risk stratification","volume":"26","author":"Delrue","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.107044_bib54","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1172\/JCI74475","article-title":"The genetics and immunobiology of IgA nephropathy","volume":"124","author":"Kiryluk","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2026.107044_bib55","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00251-012-0636-y","article-title":"Genome-wide association study identifies TNFSF13 as a susceptibility gene for IgA in a South Chinese population in smokers","volume":"64","author":"Yang","year":"2012","journal-title":"Immunogenetics"},{"key":"10.1016\/j.ekir.2026.107044_bib56","doi-asserted-by":"crossref","first-page":"6859","DOI":"10.1038\/s41467-022-34456-6","article-title":"Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ekir.2026.107044_bib60","first-page":"635","article-title":"Sibeprenlimab in IgA nephropathy \u2014 interim analysis of a Phase 3 trial","volume":"0","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.107044_bib61","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.kint.2025.05.006","article-title":"Zigakibart demonstrates clinical safety and efficacy in a Phase 1\/2 trial of healthy volunteers and patients with IgA nephropathy","volume":"108","author":"Kooienga","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.107044_bib66","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMoa2510198","article-title":"A Phase 3 trial of atacicept in patients with IgA nephropathy","volume":"394","author":"Lafayette","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.107044_bib68","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ekir.2025.10.029","article-title":"Povetacicept for IgA nephropathy and primary membranous nephropathy","volume":"11","author":"Madan","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.107044_bib70","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized Phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.107044_bib74","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1681\/ASN.2025n4b0qfm4","article-title":"Efficacy and safety of telitacicept in patients with IgAN: results from Stage A of a Phase 3 clinical study: SA-OR083","volume":"36","author":"Lv","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.107044_bib57","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ekir.2022.01.1073","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of VIS649 (sibeprenlimab), an April-neutralizing IgG2 monoclonal antibody, in healthy volunteers","volume":"7","author":"Mathur","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.107044_bib58","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","article-title":"A proliferation inducing ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy","volume":"96","author":"Myette","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.107044_bib59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A Phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.107044_bib63","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00228-007-0311-7","article-title":"Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers","volume":"63","author":"Munafo","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2026.107044_bib64","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.107044_bib65","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.0000000541","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy","volume":"36","author":"Barratt","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.107044_bib67","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/art.42462","article-title":"Povetacicept, an enhanced dual April\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell\u2013related autoimmune diseases","volume":"75","author":"Evans","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2026.107044_bib71","article-title":"Preliminary analysis of short-term real-world outcomes of telitacicept in high-risk IgA nephropathy","volume":"12","author":"Ma","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2026.107044_bib72","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","article-title":"Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy","volume":"9","author":"Zan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.107044_bib73","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10238-025-01829-2","article-title":"Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study","volume":"25","author":"Shu","year":"2025","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.ekir.2026.107044_bib75","first-page":"5181","article-title":"Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab","volume":"116","author":"Mei","year":"2010","journal-title":"IgA"},{"key":"10.1016\/j.ekir.2026.107044_bib76","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaf116.0273","article-title":"Differential impacts of April and April\/BAFF inhibition on immune populations","volume":"40","author":"Rowley","year":"2025","journal-title":"Nephrol Dial Transplant"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926032766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926032766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:30:29Z","timestamp":1793737829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926032766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2468024926032766"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.107044","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the B-Cell Activating Factor and a Proliferation-Inducing Ligand Pathway in IgAN: From Disease Pathogenesis to Clinical Trial Evidence","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.107044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"107044"}}